The thalassemias are an inherited group of heterogeneous anemias in which 1 or more of the globin chains in the hemoglobin tetramer are absent. Among the 4 classic alpha thalassemia syndromes, there ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Agios maintains a robust balance sheet and is positioned for significant growth if regulatory approvals and market expansion ...

Thalassemia is an inherited blood disorder that affects the production of hemoglobin and red blood cells. Symptoms include jaundice, chest pain, breathing problems, and more. Various complications can ...

Philadelphia, May 29, 2020 - In a report in The Journal of Molecular Diagnostics, published by Elsevier, researchers describe a rapid, accurate novel assay for nondeletional alpha-thalassemia ...

Researchers from Mahidol University have developed a rapid, high-throughput screening method for prevention and control of thalassemia. The related report by Munkongdee et al, "Rapid diagnosis of ...

Thalassemia is a common genetic condition affecting red blood cells. Children with severe forms of thalassemia often develop symptoms early in life, but effective treatment can manage the condition.

Agios Pharmaceuticals (AGIO) announced that new data on mitapivat, an oral pyruvate kinase activator, will be featured in oral and poster ...

When we think about common health issues, diabetes and high blood pressure are the most common health issues that pop into our minds. However, some other disorders are more common than we think and ...

People with thalassemia trait usually don’t have any symptoms. In certain cases, like during pregnancy, thalassemia carriers may have symptoms of mild anemia, such as fatigue or headaches. Thalassemia ...

Agios Pharmaceuticals completed its IPO in 2013 and sold its oncology portfolio for $1.8bn in 2021. Its stock price is down 50% across a 5-year period. The company's focus is now on mitapivat, which ...